Loading...
Market
Story
FDA Approves Illumina's TruSight Oncology Comprehensive for Bayer and Lilly Therapies
Aug 27, 2024, 02:01 PM
The U.S. Food and Drug Administration (FDA) has approved Illumina's TruSight Oncology Comprehensive assay, a cancer biomarker test designed to rapidly match patients to targeted therapies. This test includes two companion diagnostics and is specifically approved as a companion diagnostic (CDx) for kinase inhibitors from pharmaceutical companies Bayer and Lilly. The assay identifies patients with NTRK gene fusions who may benefit from Bayer's Vitrakvi (larotrectinib) and those with RET fusion-positive cancers who may benefit from Lilly's Retevmo (selpercatinib).
View original story
Similar markets
0-10,000 • 25%
10,001-20,000 • 25%
20,001-30,000 • 25%
Over 30,000 • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10,000 • 25%
10,000 - 20,000 • 25%
20,000 - 30,000 • 25%
More than 30,000 • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Market leader • 33%
Second place • 33%
Third place or lower • 33%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%